Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
40 Cards in this Set
- Front
- Back
compensatory changes in response to heart failure?
|
SNS activation
renin-angiotensin system activation hypertrophy |
|
detrimental effects of compensatory changes in response to heart failure?
|
SNS: worsen heart failure;
renin-angiotensin: volume overload and difficulty breathing; hypertrophy: bad remodeling |
|
ACEI use in chronic heart failure?
|
decrease symptoms
increase survival |
|
diuretics use in chronic heart failure?
|
decrease congestive symptoms by decreasing preload;
effect on survival not known |
|
beta blockers use in chronic heart failure?
|
+ other therapy decrease hospitalization and mortality;
may worsen HF initially with improvements may take months |
|
mechanism of how beta blockers help in heart failure?
|
interrupt the SNS stimulation to slow disease progression
|
|
rationale for spironolactone use in heart failure?
|
aldosterone has negative effects on heart;
decreased hospitalization and mortality |
|
combination that was shown to increase survival in blacks?
|
hydralazine and ISDN
|
|
pharmacologic treatment of heart failure?
|
ACEI
diuretics beta blockers spironolactone cardiac glycosides ARBs hydralazine + ISDN eplerenone |
|
use of eplerenone for heart failure?
|
approve for HF following acute MI in certain cases
|
|
additional drugs (parenteral) used in HF?
|
sodium nitroprusside
dobutamine dopamine milrinone nesiritide |
|
main uses of cardiac glycosides?
|
heart failure
certain arrhythmias (atrial fib) |
|
only cardiac glycoside available in US?
|
digoxin
|
|
cardiac glycosides aka?
|
digitalis
|
|
mechanism of cardiac glycosides increased contractility?
|
inhibition of sarcolemmal Na,K-ATPase leading to decreased transmembrane transport of Na and K, increased intracellular Na decreases Na-Ca exchange so there is less Ca available at level of contractile proteins
|
|
actions of cardiac glycosides?
|
increased contractility
vagal stimulation decreased SNS activity |
|
conduction velocity corresponds to which phase of AP?
|
slope of phase 0
|
|
automaticity relates to which phase of AP?
|
slope phase 4
|
|
important action of cardiac glycosides that for treatment of supraventricular tachyarrhythmias, such as atrial fib?
|
vagal stimulation to slow conduction through the AV node
|
|
cardiac glycosides effects on electrophysiology of heart?
|
direct and indirect
effect depends on type of cardiac cell beneficial effect in atrial fib (decreased ventricular rate) arrhythmias and heart block possible at toxic concentrations |
|
elimination of digoxin and consequence?
|
2/3 eliminated unchanged in urine so clearance reduced in renal insufficiency and necessary to reduce dose
|
|
adverse effects of digitalis?
|
cardiac toxicity
GI (anorexia, n/v, diarrhea) CNS (blurred vision, abnormal color vision, confusion, etc) |
|
red flags for digoxin toxicity?
|
GI symptoms of anorexia, nausea and vomiting, or diarrhea
|
|
what population are adverse CNS effects with digoxin seen and what are they?
|
elderly:
blurred vision abnormal color vision confusion other mental disturbances |
|
treatment for digoxin toxicity?
|
stop drug
serum K management arrhythmia and heart block management ovine digoxin immune fab |
|
electrolyte disturbances increasing risk of digitalis toxicity?
|
hypokalemia
hypercalcemia hypomagnesemia |
|
thiazide or loop diuretic + digoxin interaction?
|
hypokalemia
|
|
digoxin + quinidine interaction?
|
increased plasma digoxin concentration
|
|
digoxin + verapamil or amiodarone interaction?
|
increased plasma digoxin concentration
|
|
digoxin + antacids, kaolin-pectin, cholestyramine interaction?
|
decreased plasma digoxin concentration due to decreased absorption
|
|
dobutamine actions?
|
β1 agonist: increase CO with less reflex tachycardia than occurs with nonselective β agonists
|
|
possible adverse effects with dobutamine?
|
excessive increase in heart rate
arrhythmias |
|
milrinone mechanism?
|
inhibits phosphodiesterase 3 --> increase cAMP --> increased contractility and vasodilation
|
|
milrinone effects in patients with HF?
|
decreased PWP
decreased peripheral resistance increased CO |
|
milrinone indications?
|
only IV for acute heart failure or severe exacerbation of chronic heart failure
|
|
nesiritide?
|
recombinant human B-type natriuretic peptide; hBNP
|
|
nesiritide mechanism?
|
action on guanylate cyclase receptor --> increased cGMP --> smooth muscle relaxation
|
|
adverse effects of nesiritide?
|
hypotension
renal damage and death |
|
indications for nesiritide?
|
use in certain patients with acute decompensated heart failure
|
|
effects of nesiritide?
|
decreased PWP and dyspnea
|